GILEAD SCIENCES, INC. (GILD) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $674.00M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value $50.00M; Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value $3.70B; Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $674.00M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $674.00M |
| Deferred revenue · latest quarter (USD) | $50.00M | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due within 1 year (USD) | $3.70B | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Reported amount: $3.70B |
| Other obligations · due after 1 year (USD) | (m) | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | (m) | |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Amounts owed to suppliers | 674.00M USD | Accounts Payable, Current |
| Total deferred revenue | 50.00M USD | Contract with Customer, Liability · Deferred Revenue, Current · Deferred Revenue, Noncurrent |
| Deferred revenue due within one year | (m) | Deferred Revenue, Current |
| Deferred revenue due after one year | (m) | Deferred Revenue, Noncurrent · Contract with Customer, Liability · Deferred Revenue, Current |
| Reported other obligations due within one year | 3.70B USD | Other Liabilities, Current |
| Reported other noncurrent obligations | 1.49B USD | Other Liabilities, Noncurrent |
| Deferred revenue included in other noncurrent obligations | (m) | Contract with Customer, Liability · Deferred Revenue, Current |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- $3.70B
- Other obligations · due after 1 year (USD)
- (m)
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Obligation categories | (m) |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $674.00M | $50.00M | $3.70B | (m) | (m) | (m) | (m) | (m) | $1.49B | (m) |
| 2026-03-31 | (m) | $645.00M | $47.00M | $3.40B | (m) | (m) | (m) | (m) | (m) | $1.20B | (m) |
| 2025-12-31 | (m) | $715.00M | $48.00M | $3.95B | (m) | (m) | (m) | (m) | (m) | $1.17B | (m) |
| 2025-09-30 | (m) | $808.00M | $56.00M | $3.75B | (m) | (m) | (m) | (m) | (m) | $1.18B | (m) |
| 2025-06-30 | (m) | $582.00M | $58.00M | $3.59B | (m) | (m) | (m) | (m) | (m) | $1.29B | (m) |
| 2025-03-31 | (m) | $737.00M | $56.00M | $4.62B | (m) | (m) | (m) | (m) | (m) | $1.34B | (m) |
| 2024-12-31 | (m) | $833.00M | $58.00M | $5.46B | (m) | (m) | (m) | (m) | (m) | $1.29B | (m) |
| 2024-09-30 | (m) | $903.00M | $68.00M | $4.90B | (m) | (m) | (m) | (m) | (m) | $1.40B | (m) |
| 2024-06-30 | (m) | $537.00M | $76.00M | $4.51B | (m) | (m) | (m) | (m) | (m) | $1.42B | (m) |
| 2024-03-31 | (m) | $622.00M | $84.00M | $4.46B | (m) | (m) | (m) | (m) | (m) | $1.40B | (m) |
| 2023-12-31 | (m) | $550.00M | $109.00M | $5.13B | (m) | (m) | (m) | (m) | (m) | $1.28B | (m) |
| 2023-09-30 | (m) | $586.00M | $68.00M | $5.85B | (m) | (m) | (m) | (m) | (m) | $924.00M | (m) |
| 2023-06-30 | (m) | $622.00M | $103.00M | $5.81B | (m) | (m) | (m) | (m) | (m) | $1.35B | (m) |
| 2023-03-31 | (m) | $627.00M | $93.00M | $4.14B | (m) | (m) | (m) | (m) | (m) | $1.28B | (m) |
| 2022-12-31 | (m) | $905.00M | $102.00M | $4.58B | (m) | (m) | (m) | (m) | (m) | $1.18B | (m) |
| 2022-09-30 | (m) | $614.00M | $85.00M | (m) | (m) | (m) | (m) | (m) | (m) | $1.11B | (m) |
| 2022-06-30 | (m) | $565.00M | $98.00M | (m) | (m) | (m) | (m) | (m) | (m) | $988.00M | (m) |
| 2022-03-31 | (m) | $583.00M | $117.00M | (m) | (m) | (m) | (m) | (m) | (m) | $944.00M | (m) |
| 2021-12-31 | (m) | $705.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $976.00M | (m) |
| 2021-09-30 | (m) | $585.00M | $85.00M | (m) | (m) | (m) | (m) | (m) | (m) | $962.00M | (m) |
| 2021-06-30 | (m) | $608.00M | $87.00M | (m) | (m) | (m) | (m) | (m) | (m) | $1.18B | (m) |
| 2021-03-31 | (m) | $570.00M | $91.00M | (m) | (m) | (m) | (m) | (m) | (m) | $1.43B | (m) |
| 2020-12-31 | (m) | $844.00M | $97.00M | (m) | (m) | (m) | (m) | (m) | (m) | $5.13B | (m) |
| 2020-09-30 | (m) | $527.00M | $103.00M | (m) | (m) | (m) | (m) | (m) | (m) | $1.09B | (m) |
| 2020-06-30 | (m) | $532.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.02B | (m) |
| 2020-03-31 | (m) | $590.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $990.00M | (m) |
| 2019-12-31 | (m) | $713.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.01B | (m) |
| 2019-09-30 | (m) | $632.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $901.00M | (m) |
| 2019-06-30 | (m) | $617.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.58B | (m) |
| 2019-03-31 | (m) | $577.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.46B | (m) |
| 2018-12-31 | (m) | $790.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.04B | (m) |
| 2018-09-30 | (m) | $580.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $594.00M | (m) |
| 2018-06-30 | (m) | $623.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $646.00M | (m) |
| 2018-03-31 | (m) | $711.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $671.00M | (m) |
| 2018-01-01 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $589.00M | (m) |
| 2017-12-31 | (m) | $814.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $558.00M | (m) |
| 2017-09-30 | (m) | $696.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $259.00M | (m) |
| 2017-06-30 | (m) | $819.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $442.00M | (m) |
| 2017-03-31 | (m) | $944.00M | (m) | (m) | (m) | (m) | (m) | $245.00M | (m) | $333.00M | (m) |
| 2016-12-31 | (m) | $1.21B | (m) | (m) | (m) | (m) | (m) | $202.00M | (m) | $296.00M | (m) |
| 2016-09-30 | (m) | $1.05B | (m) | (m) | (m) | (m) | (m) | $361.00M | (m) | $184.00M | (m) |
| 2016-06-30 | (m) | $1.12B | (m) | (m) | (m) | (m) | (m) | $345.00M | (m) | $467.00M | (m) |
| 2016-03-31 | (m) | $945.00M | (m) | (m) | (m) | (m) | (m) | $529.00M | (m) | $374.00M | (m) |
| 2015-12-31 | (m) | $1.18B | (m) | (m) | (m) | (m) | (m) | $440.00M | (m) | $395.00M | (m) |
| 2015-09-30 | (m) | $1.24B | (m) | (m) | (m) | (m) | (m) | $356.00M | (m) | $378.00M | (m) |
| 2015-06-30 | (m) | $1.57B | (m) | (m) | (m) | (m) | (m) | $501.00M | (m) | $760.00M | (m) |
| 2015-03-31 | (m) | $1.01B | (m) | (m) | (m) | (m) | (m) | $191.00M | (m) | $619.00M | (m) |
| 2014-12-31 | (m) | $955.00M | (m) | (m) | (m) | (m) | (m) | $134.00M | (m) | $535.00M | (m) |
| 2014-09-30 | (m) | $1.18B | (m) | (m) | (m) | (m) | (m) | $116.88M | (m) | $482.54M | (m) |
| 2014-06-30 | (m) | $1.16B | (m) | (m) | (m) | (m) | (m) | $126.28M | (m) | $174.20M | (m) |
| 2014-03-31 | (m) | $1.23B | (m) | (m) | (m) | (m) | (m) | $111.79M | (m) | $174.94M | (m) |
| 2013-12-31 | (m) | $1.26B | $132.62M | (m) | $156.65M | (m) | (m) | $110.64M | $21.98M | $156.65M | $0.00 |
| 2013-09-30 | (m) | $1.35B | $152.68M | (m) | $261.09M | (m) | (m) | $127.28M | $25.40M | $261.09M | $0.00 |
| 2013-06-30 | (m) | $1.39B | $140.89M | (m) | $224.63M | (m) | (m) | $112.12M | $28.77M | $224.63M | $0.00 |
| 2013-03-31 | (m) | $1.36B | $156.57M | (m) | $213.33M | (m) | (m) | $124.37M | $32.20M | $213.33M | $0.00 |
| 2012-12-31 | (m) | $1.33B | $123.69M | (m) | $228.04M | (m) | (m) | $103.16M | $20.53M | $228.04M | $0.00 |
| 2012-09-30 | (m) | $1.32B | $119.88M | (m) | $221.65M | (m) | (m) | $99.05M | $20.84M | $221.65M | $0.00 |
| 2012-06-30 | (m) | $1.37B | $117.32M | (m) | $155.19M | (m) | (m) | $93.66M | $23.66M | $155.19M | $0.00 |
| 2012-03-31 | (m) | $1.34B | $126.70M | (m) | $153.99M | (m) | (m) | $100.19M | $26.51M | $153.99M | $0.00 |
| 2011-12-31 | (m) | $1.21B | $106.53M | (m) | $147.74M | (m) | (m) | $74.67M | $31.87M | $147.74M | $0.00 |
| 2011-09-30 | (m) | $1.06B | $103.38M | (m) | $138.77M | (m) | (m) | $68.67M | $34.70M | $138.77M | $0.00 |
| 2011-06-30 | (m) | $1.10B | $90.95M | (m) | $156.39M | (m) | (m) | $63.24M | $27.71M | $156.39M | $0.00 |
| 2011-03-31 | (m) | $981.63M | $127.65M | (m) | $49.80M | (m) | (m) | $97.37M | $30.27M | $49.80M | $0.00 |
| 2010-12-31 | (m) | $803.02M | $136.02M | (m) | $27.40M | (m) | (m) | $103.17M | $32.84M | $27.40M | $0.00 |
| 2010-09-30 | (m) | $950.81M | $135.24M | (m) | $47.76M | (m) | (m) | $95.79M | $39.45M | $47.76M | $0.00 |
| 2010-06-30 | (m) | $1.07B | $155.89M | (m) | $23.05M | (m) | (m) | $116.36M | $39.53M | $23.05M | $0.00 |
| 2010-03-31 | (m) | $949.08M | $163.73M | (m) | $27.29M | (m) | (m) | $122.24M | $41.49M | $27.29M | $0.00 |
| 2009-12-31 | (m) | $810.54M | $165.75M | (m) | $35.92M | (m) | (m) | $122.72M | $43.03M | $35.92M | $0.00 |
| 2009-09-30 | (m) | $742.68M | $93.93M | (m) | $42.36M | (m) | (m) | $49.36M | $44.57M | $42.36M | $0.00 |
| 2009-06-30 | (m) | $650.00M | $99.76M | (m) | $50.08M | (m) | (m) | $46.34M | $53.42M | $50.08M | $0.00 |
| 2008-12-31 | (m) | $601.20M | $117.14M | (m) | $21.46M | (m) | (m) | $42.96M | $74.18M | $21.46M | $0.00 |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |